Cidara Therapeutics Inc CDTX:NASDAQ

Last Price$0.83NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.03(3.95%)
Bid (Size)$0.83 (1)
Ask (Size)$0.97 (2)
Day Low / High$0.82 - 0.89
Volume336.7 K

View Biotechnology IndustryPeer Comparison as of 01/21/2022


Cidara Therapeutics Inc ( NASDAQ )

Price: $0.83
Change: -0.03 (3.95%)
Volume: 336.7 K
4:00PM ET 1/21/2022

Genocea Biosciences Inc ( NASDAQ )

Price: $0.96
Change: -0.05 (4.97%)
Volume: 235.0 K
4:00PM ET 1/21/2022

Aravive Inc ( NASDAQ )

Price: $2.23
Change: -0.05 (2.19%)
Volume: 54.9 K
4:00PM ET 1/21/2022

Ocuphire Pharma Inc ( NASDAQ )

Price: $3.09
Change: -0.11 (3.44%)
Volume: 453.9 K
4:00PM ET 1/21/2022

GlycoMimetics Inc ( NASDAQ )

Price: $1.11
Change: -0.07 (5.93%)
Volume: 369.2 K
4:00PM ET 1/21/2022

Read more news Recent News

Wedbush Lifts Cidara Therapeutics' Price Target to $6 From $5 on Echinocandin Rezafungin Trial Data; Outperform Rating Kept
7:54AM ET 12/16/2021 MT Newswires

Cidara Therapeutics (CDTX) has an average rating of buy and price targets ranging from $5 to $8, according to analysts polled by Capital IQ. (MT Newswires...

Cidara Therapeutics, Mundipharma Say Fungal Infections Treatment Met Primary Goals in Late-Stage Trial
8:02AM ET 12/14/2021 MT Newswires

Cidara Therapeutics (CDTX) and Mundipharma said Tuesday a phase 3 trial of rezafungin met its primary endpoints as a treatment for fungal infections versus...

-- Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q3 Revenue $7.1M
4:23PM ET 11/10/2021 MT Newswires


Cidara Therapeutics Raises Gross Proceeds of $38.5 Million From Two Public Offerings
4:18PM ET 10/13/2021 MT Newswires

Cidara Therapeutics (CDTX) said that it has closed on concurrent public offerings of common and preferred stock, raising gross proceeds of approximately...

View all Commentary and Analysis

Cidara Therapeutics (CDTX) Investor Presentation - Slideshow
1:32PM ET 10/07/2021 Seeking Alpha

Cidara Therapeutics (CDTX) Investor Presentation - Slideshow
4:11PM ET 9/17/2021 Seeking Alpha

Cidara Therapeutics: Rezafungin Data Could Bring Value
5:33AM ET 7/20/2021 Seeking Alpha

Checking Back In On Cidara Therapeutics
7:09AM ET 3/27/2021 Seeking Alpha

Company Profile

Business DescriptionCidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA. View company web site for more details
Address6310 Nancy Ridge Drive
San Diego, California 92121
Number of Employees68
Recent SEC Filing01/07/20224
President, Chief Executive Officer & DirectorJeffrey L. Stein
Chief Operating OfficerPaul Daruwala
Chief Financial & Business OfficerPreetam Shah
Senior Vice President-ResearchLes Tari

Company Highlights

Price Open$0.86
Previous Close$0.86
52 Week Range$0.82 - 3.15
Market Capitalization$55.1 M
Shares Outstanding66.7 M
SectorHealth Technology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.06
Beta vs. S&P 500N/A
Net Profit Margin-106.76%
Return on Equity-722.37%

Analyst Ratings as of 12/30/2021

Consensus RecommendationConsensus Icon
Powered by Factset